FDA Approves 11 ZYN ULTRA Nicotine Pouches, Expanding PMI's U.S. Portfolio
PM sits 34% above its 52-week low of $142.11.
Summary
The FDA granted marketing orders for 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. This expands PMI's authorized U.S. portfolio beyond the earlier ZYN authorizations in 3mg and 6mg strengths. The approval is a material regulatory win for the company's smoke-free strategy, though additional 11mg variants remain under review. The news follows the June 30 FDA authorization of ZYN pouches as less harmful alternatives, reinforcing PMI's regulatory momentum in the U.S. market.
At the time of this announcement, PM was trading at $189.94 on NYSE in the Trade & Services sector, with a market capitalization of approximately $293.4B. The 52-week trading range was $142.11 to $207.76. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: dpa-AFX.